… disease (PD)? Maybe, says a new population-based study from researchers at National Taiwan University in Taipei, … risk.  Last year, we reported on a similar study from Harvard Medical School that found that those taking …

… same time reducing dyskinesias. But today’s results, culled from three concurrent phase 3 trials, showed that … a company called Biotie announced positive phase 2 results from a similar treatment called tozadenant.  The company had …

… PhD, says: “This decision shouldn’t impede research groups from making a drug that targets a genetic mutation or using information gleaned from understanding the mutation to inform drug development.” …

… Parkinson’s patients suffering from orthostatic hypotension — a sudden drop in blood … since 1989. It was a long journey for the drug candidate from Chelsea Therapeutics; the FDA denied approval and asked …

… of the disease through her choreography, tracking movement from fluid to halting. Nicole Kelleners, an advancement … Foundation of Western PA. There is a real buzz and interest from the Parkinson’s community there! Read more of The …

… to participate in a successful trial and receive a benefit from a drug that may still have years of research before … research today, so that maybe they will not have to suffer from some of these diseases tomorrow. Sign up for Fox Trial …